Pharmaserv

Name

Pharmaserv

Legal name

INNEXIS

Website

https://pharmaserv.de

Company type

Private

Founded year

1997

Headcount range

101–250 employees

Ownership category

akta.pro rank

Product category

Pharmaceutical & Life Science Park Operations

NAICS

General Medical and Surgical Hospitals (6221), RV (Recreational Vehicle) Parks and Campgrounds (721211)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Pharmaceutical Preparations (2834), Services-Medical Laboratories (8071)

akta.pro primary industry

Hospital & Health-System Pharmaceutical Distributors (HLAIAJAD)

akta.pro secondary industries

Specialty Pharma & Biologics Distribution (GDP-compliant) (HLAGAMAD), Clinical Trial Pharmacy & IMP Management at Site (HLAGACAK)

Keywords

• Pharma park operations
• GxP-compliant infrastructure
• Pharmaceutical site management
• Engineering qualification validation
• Pharma logistics services

Headquarters

HQ city

Marburg

HQ country

Germany

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Operations, Infrastructure, Personnel, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. Real estate / park leasing: Long-term leases of office, laboratory, production and warehouse space plus open land on the Marburg (67.4 ha), Jena (~24,000 m²) and Orth (~240,000 m²) parks to pharma, biotech and medtech tenants.
2. Site management services: 24/7 site management, facilities, utilities, site security, waste disposal and project planning/development services sold to tenants of the parks.
3. Engineering services: Consulting & conception, engineering & design, production technology, qualification & validation, and plant maintenance services for pharma clients.
4. Pharma logistics services: Pharma logistics, production logistics, transport management and the Pharma Shop for operating supplies, provided to park tenants and external clients.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels7 records

Core offering

Pharmaserv (operating as INNEXIS) owns and operates three GxP-compliant Pharma & Life Science Parks in Marburg, Jena (Germany) and Orth (Austria), and sells bundled site management, engineering and pharma logistics services to pharma, biotech and medtech tenants. The Marburg park (67.4 ha, ~200 buildings, ~7,000 tenant employees, historically the Behringwerke) is the flagship site; integrated offerings span facilities, utilities, dedicated power-grid operation, qualification & validation, plant maintenance, transport management and an online Pharma Shop.

Product overview

Pharmaserv (represented here by the INNEXIS website content) operates a platform-plus-modules architecture centered on its Pharma & Life Science Parks — the Pharma & Life Science Park Marburg (the largest at 67.4 hectares with ~200 buildings and ~7,000 employees), the Pharma & Life Science Park Jena (around 24,000 m²) and the Pharma & Life Science Park Orth (around 240,000 m² of GxP-compliant space). As both owner and operator of these parks, the company delivers integrated site management (Facilities, Utilities, Site Services, Project Planning & Development), an Engineering solutions stack (Beratung & Konzeption, Engineering & Design, Fertigungstechnik, Qualifizierung & Validierung, Anlageninstandhaltung) and a Logistics solutions stack (Pharmalogistik, Produktionslogistik, Transportmanagement, Pharma Shop). Complementary offerings referenced in the site footer include the Innovation Hub Marburg, Solution Center, Lead Logistic Provider, ISO-Kalibriertechnik, Reinraumtechnik, Typenqualifizierung, Labor mieten, Produktionsfläche mieten and Netzbetrieb (Strom). All offerings tie back to the core parks as the operational foundation, with the Engineering, Logistics and Site Management modules providing the specialized services that allow pharma and life science tenants (such as CSL, BioNTech, GSK Vaccines, Siemens Healthineers, UKGM and IQVIA) to operate on a GxP-compliant basis.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• 67.4 ha of fully developed park land with 200 buildings, 9.4 ha open space and 60,000 m² yard/road area
• +3 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Nine partnerships are on record, tiered core, minor and flagship.

• Philipps-Universität MarburgcoreStrategic or Co-development PartnerAdjacent university in the Marburg science region; provides direct access to research, cooperation partners and a pool of qualified talent for park tenants. Referenced as part of the company's value proposition for the Marburg park.
• Max-Planck-Institut für terrestrische Mikrobiologie (Max Planck Institute for Terrestrial Microbiology)coreStrategic or Co-development PartnerLocated in immediate proximity to the Marburg park; highlighted as part of the dynamic science region enabling tenant access to innovation, collaboration and talent.
• Universities and colleges in Gießen and Friedberg (Hochschulen in Gießen und Friedberg)minorStrategic or Co-development PartnerReferenced as part of the regional science ecosystem feeding talent and innovation into the Marburg park.
• CSLflagshipStrategic or Co-development PartnerListed as a globally leading company "already on site" in the Marburg park, anchoring the cluster's tenant base and ecosystem reputation.
• BioNTechflagshipStrategic or Co-development PartnerHighlighted as a globally leading company on-site at the Marburg park; the site is specifically credited with proving its importance during the coronavirus pandemic.
• GSK VaccinesflagshipStrategic or Co-development PartnerListed among globally leading companies established at the Marburg park, contributing to its vaccine/biologics cluster.
• Siemens HealthineersflagshipStrategic or Co-development PartnerListed as a globally leading company on-site at the Marburg park, anchoring the medtech presence in the cluster.
• UKGM (Universitätsklinikum Gießen und Marburg)flagshipStrategic or Co-development PartnerListed as a globally leading company on-site at the Marburg park, providing clinical and translational research adjacency.
• IQVIAflagshipStrategic or Co-development PartnerListed as a globally leading company on-site at the Marburg park, adding clinical-research and life-science services depth to the cluster.

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• BioMed Realty (Blackstone): Life science real estate platform owned by Blackstone, operating lab and GMP manufacturing campuses across major US innovation hubs. Comparable as a life science-focused real estate operator with bundled services, though at much greater scale and US-centric.
• Alexandria Real Estate Equities: Large US-listed REIT focused on life science real estate clusters in Boston, San Francisco, San Diego, Research Triangle and other innovation hubs. A much larger and broader incumbent that competes for global life science tenants and provides a valuation benchmark for specialized life science real estate operators.
• VGP Group: European logistics and industrial real estate developer/operator with parks across Germany, Czech Republic, Spain and other markets. Comparable on the multi-park industrial real estate model, though more generalist than Pharmaserv's pharma-specialized focus.
• Healthpeak Properties: US-listed REIT with a significant life science and medical office portfolio serving pharma, biotech and medtech tenants across innovation hubs. Comparable on the specialized life science real estate thesis and tenant overlap, though US-centric and capital-markets-driven.
• Goodman Group: Global industrial and logistics real estate specialist operating business and industrial parks in Europe, Asia-Pacific and the Americas, with growing exposure to life science and data center tenants. Comparable on the multi-park infrastructure model at much greater scale and broader scope.

Direct peers

• Kadans Science Partner: European specialist operator and developer of science parks and lab buildings across the Netherlands, UK, Germany and beyond, serving life science tenants with flexible lab and production space. Directly comparable as a science-park specialist competing for the same European life science tenant base.
• Infraserv Höchst: Operates Industriepark Höchst near Frankfurt, one of Germany's largest chemical/pharma parks with a similar integrated site-services model including utilities, site management and GxP infrastructure. It is the closest structural analogue to Pharmaserv's Marburg park, serving global pharma tenants under a one-stop-shop framework.
• InfraServ Knapsack: Operates the Knapsack industrial site near Cologne, providing infrastructure, energy supply, and site services to chemical and specialty industrial tenants. Closely mirrors Pharmaserv's German industrial-site-operator model at smaller scale.
• Currenta GmbH (Chempark): Operates Chempark sites in Leverkusen, Dormagen and Krefeld-Uerdingen with Bayer and other global chemical/pharma tenants, providing site management, utilities, logistics and engineering services under an integrated model comparable to Pharmaserv's offering.

Others

• Sanofi Gentilly / Lonza Visp site operations: Lonza's Visp (Switzerland) integrated manufacturing campus is the leading European example of an integrated biotech manufacturing site with on-site logistics, utilities and services for multiple tenants. Adjacent rather than directly comparable, but illustrates the ultimate scale and integration benchmark that a successful European life science park operator can attain.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pharmaserv